Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems
NP Staff, JC Fehrenbacher, M Caillaud, MI Damaj… - Experimental …, 2020 - Elsevier
Abstract Paclitaxel (Brand name Taxol) is widely used in the treatment of common cancers
like breast, ovarian and lung cancer. Although highly effective in blocking tumor progression …
like breast, ovarian and lung cancer. Although highly effective in blocking tumor progression …
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating
condition associated with a number of chemotherapeutic agents. Drugs commonly …
condition associated with a number of chemotherapeutic agents. Drugs commonly …
Perceived stress is associated with a higher symptom burden in cancer survivors
Background Although multiple co‐occurring symptoms are a significant problem for cancer
survivors, to the authors' knowledge little is known regarding the phenotypic characteristics …
survivors, to the authors' knowledge little is known regarding the phenotypic characteristics …
Psychometric properties of the Chinese version of the Pittsburgh Sleep Quality Index (PSQI) among Hong Kong Chinese childhood cancer survivors
Background Sleep disruption is a prevalent symptom reported by survivors of childhood
cancer. However, there is no validated instrument for assessing this symptom in this …
cancer. However, there is no validated instrument for assessing this symptom in this …
A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms
Background Chemotherapy-induced peripheral neuropathy (CIPN) can result in functional
difficulties. Pharmacological interventions used to prevent CIPN either show low efficacy or …
difficulties. Pharmacological interventions used to prevent CIPN either show low efficacy or …
The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a …
OR Phillips, DM Baguley, SE Pearson… - Journal of Cancer …, 2023 - Springer
Purpose To elucidate the long-term impacts of hearing loss, tinnitus and balance in people
living with and beyond cancer (LWBC) treated with platinum-based chemotherapy (PBCT) …
living with and beyond cancer (LWBC) treated with platinum-based chemotherapy (PBCT) …
A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse
X Lin, Z Xu, L Carey, J Romero, A Makriyannis… - Pain, 2022 - journals.lww.com
Abstract CB2 cannabinoid receptors (CB2) are a promising therapeutic target that lacks
unwanted side effects of CB1 activation. However, the cell types expressing CB2 that …
unwanted side effects of CB1 activation. However, the cell types expressing CB2 that …
Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors
KM Kober, A Olshen, YP Conley… - Molecular …, 2018 - journals.sagepub.com
Background Paclitaxel is one of the most commonly used drugs to treat breast cancer. Its
major dose-limiting toxicity is paclitaxel-induced peripheral neuropathy (PIPN). PIPN …
major dose-limiting toxicity is paclitaxel-induced peripheral neuropathy (PIPN). PIPN …
Alphalipoic acid prevents oxidative stress and peripheral neuropathy in nab‐paclitaxel‐treated rats through the Nrf2 signalling pathway
H Sun, X Guo, Z Wang, P Wang… - Oxidative medicine …, 2019 - Wiley Online Library
Peripheral neuropathy is the major dose‐limiting side effect of paclitaxel (PTX), affecting
both the quality of life and the survival of cancer patients. Nab‐paclitaxel (nab‐PTX) was …
both the quality of life and the survival of cancer patients. Nab‐paclitaxel (nab‐PTX) was …
Vestibulotoxicity associated with platinum-based chemotherapy in survivors of cancer: a scoping review
P Prayuenyong, JA Taylor, SE Pearson… - Frontiers in …, 2018 - frontiersin.org
Background: Cochleotoxicity following the treatment with platinum-based chemotherapy is
well documented. The potential for vestibulotoxicity is still unclear. This scoping review …
well documented. The potential for vestibulotoxicity is still unclear. This scoping review …